Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
19 hedge funds and large institutions have $56.4M invested in Agile Therapeutics in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
6% more funds holding
Funds holding: 18 → 19 (+1)
20% less capital invested
Capital invested by funds: $70.2M → $56.4M (-$13.8M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$479K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$216K |
| 3 |
LPL Financial
San Diego,
California
|
+$77.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$77.2K |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$61.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.17M |
| 2 |
Millennium Management
New York
|
-$975K |
| 3 |
VAM
Visium Asset Management
New York
|
-$943K |
| 4 |
Morgan Stanley
New York
|
-$232K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$216K |
AGRX Hedge Fund Activity: Q3 2014 in Review
19 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2014, worth a combined $56.4M — down 20% from $70.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AGRX positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $479K. The largest seller was Alyeska Investment Group, cutting an estimated $1.17M.
- 19 institutional investors held Agile Therapeutics (AGRX) as of Q3 2014, up from 18 in Q2 2014.
- Funds reported $56.4M of Agile Therapeutics stock for Q3 2014, down 20% quarter-over-quarter.
- 5 funds opened new Agile Therapeutics positions in Q3 2014 and 4 closed out, a net change of +1 holder.
- The largest Agile Therapeutics buyer in Q3 2014 was Goldman Sachs, an estimated $479K added.
- The largest Agile Therapeutics seller in Q3 2014 was Alyeska Investment Group, an estimated $1.17M sold.
Based on aggregated 13F filings for Q3 2014.